J&J, Lilly hail new data on potential diabetes drugs

Johnson & Johnson ($JNJ), Eli Lilly ($LLY) and Boehringer Ingelheim touted new late-stage data supporting their experimental diabetes drugs, part of the SGLT2 class. Another potential product in the same class, developed by AstraZeneca ($AZN) and Bristol-Myers Squibb ($BMY), was nixed by FDA early this year on safety concerns. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.